Citations

Showing 10 of 108083 citations.

Concise Review: Multifaceted Characterization of Human Mesenchymal Stem Cells for Use in Regenerative Medicine
Samsonraj, Rebekah M. , Raghunath, Michael , Nurcombe, Victor , Hui, James Hoi Po , Wijnen, André J. van , Cool, Simon M. , van Wijnen, Andre J

Mayo Clinic

Stem Cells Translational Medicine | October 27, 2017 | Volume: 6 | Issue: 12 | Pages: 2173-2185

10.1002/sctm.17-0129 | PMID 29076267 Get It

Abstract Mesenchymal stem cells (MSC) hold great potential for regenerative medicine because of their ability for self-renewal and differentiation into tissue-specific cells such as osteoblasts, chondrocytes, and adipocytes. MSCs orchestrate tissue development, maintenance and repair, and are useful for musculoskeletal regenerative therapies to treat age-related orthopedic degenerative diseases and other clinical conditions. Importantly, MSCs produce secretory factors that play critical roles in tissue repair that support both engraftment and trophic functions (autocrine and paracrine). The development of uniform protocols for both preparation and characterization of MSCs, including standardized functional assays for evaluation of their biological potential, are critical factors contributing to their clinical utility. Quality control and release criteria for MSCs should include cell surface markers, differentiation potential, and other essential cell parameters. For example, cell surface marker profiles (surfactome), bone-forming capacities in ectopic and orthotopic models, as well as cell size and granularity, telomere length, senescence status, trophic factor secretion (secretome), and immunomodulation, should be thoroughly assessed to predict MSC utility for regenerative medicine. We propose that these and other functionalities of MSCs should be characterized prior to use in clinical applications as part of comprehensive and uniform guidelines and release criteria for their clinical-grade production to achieve predictably favorable treatment outcomes for stem cell therapy.
Healthcare Simulation Education: Evidence, Theory and Practice, 1st ed.
Torsher, Laurence C.

Mayo Clinic

Anesthesia & Analgesia | October 26, 2017 | Volume: 126 | Issue: 1 | Pages: 357-357

10.1213/ane.0000000000002568 Get It

International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma
Ellin, Fredrik , Srour, Line, Slack, Graham W. , Smedby, Karin E. , Ansell, Stephen M. , Link, Brian K. , Relander, Thomas, Jerkeman, Mats, Connors, Joseph M. , Savage, Kerry J. , Link, Brian K , Maurer, Matthew J. , Jerkeman, Mats , Bennani, N. Nora , Cerhan, James R. , Feldman, Andrew L.

Mayo Clinic

Journal of Clinical Oncology | October 26, 2017 | Volume: 35 | Issue: 36 | Pages: 4019-4026

10.1200/jco.2017.73.8195 | PMID 29072976 Get It

Purpose Peripheral T-cell lymphomas (PTCLs) have aggressive clinical behavior. We have previously shown that event-free survival (EFS) at 24 months (EFS24) is a clinically useful end point in diffuse large B-cell lymphoma. Here, we assess EFS24 and subsequent overall survival (OS) in large, multinational PTCL cohorts. Patients and Methods Patients with systemic PTCL newly diagnosed from 2000 to 2012 and treated with curative intent were included from the United States and Sweden (initial cohorts) and from Canada (replication cohort). EFS was defined as time from date of diagnosis to progression after primary treatment, retreatment, or death. Subsequent OS was measured after achieving EFS24 or from the time of progression if it occurred within 24 months. OS rates were compared with the age-, sex-, and country-matched general population. Results Seven hundred seventy-five patients were included in the study (the median age at diagnosis was 64 years; 63% were men). Results were similar in the initial and replication cohorts, and a combined analysis was undertaken. Sixty-four percent of patients progressed within the first 24 months and had a median OS of only 4.9 months (5-year OS, 11%). In contrast, median OS after achieving EFS24 was not reached (5-year OS, 78%), although relapses within 5 years of achieving EFS24 occurred in 23% of patients. Superior outcomes after achieving EFS24 were observed in younger patients (≤ 60 years of age: 5-year OS, 91%). Conclusion EFS24 stratifies subsequent outcome in PTCL. Patients with PTCL with primary refractory disease or early relapse have extremely poor survival. However, more than one third of patients with PTCL remain in remission 2 years after diagnosis with encouraging subsequent OS, especially in younger patients. These marked differences in outcome suggest that EFS24 has utility for patient counseling, study design, and risk stratification in PTCL.
Travelers’ diarrhea in children: a blind spot in the expert panel guidelines on prevention and treatment
Hagmann, Stefan , Christenson, John C. , Medicine, on behalf of the Pediatric Interest Group, International Society of Travel, Fischer, Philip R. , Medicine, on behalf of the Pediatric Interest Group, International Society of Travel

Mayo Clinic

Journal of Travel Medicine | October 26, 2017 | Volume: 25 | Issue: 1 | Pages: No page available

10.1093/jtm/tax075 | PMID 29394391 Get It

Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma
Tran, Nhan L. , Halperin, Rebecca F. , Phillips, Joanna J. , Kuhn, John G. , Groot, John F. de, Colman, Howard , Wen, Patrick Y. , Mellinghoff, Ingo K. , Butowski, Nicholas , Taylor, Jennie , Clarke, Jennifer , Chang, Susan M. , Molinaro, Annette M. , Maggiora, Gerald M. , Peng, Sen, Liang, Winnie S. , Trent, Jeffrey M. , Berens, Michael E. , Carpten, John D. , Craig, David W. , Prados, Michael D. , Berens, Michael E , Byron, Sara A. , Colman, Howard , Ligon, Keith L , Wen, Patrick Yung , Cloughesy, Timothy F. , Chang, Susan Marina , Berger, Mitchel S. , Molinaro, Annette M. , Nasser, Sara A. , Mellinghoff, Ingo K , Tran, Nhan L

Mayo Clinic

Clinical Cancer Research | October 26, 2017 | Volume: 24 | Issue: 2 | Pages: 295-305

10.1158/1078-0432.ccr-17-0963 | PMID 29074604 Get It

Abstract Purpose: Glioblastoma is an aggressive and molecularly heterogeneous cancer with few effective treatment options. We hypothesized that next-generation sequencing can be used to guide treatment recommendations within a clinically acceptable time frame following surgery for patients with recurrent glioblastoma. Experimental Design: We conducted a prospective genomics-informed feasibility trial in adults with recurrent and progressive glioblastoma. Following surgical resection, genome-wide tumor/normal exome sequencing and tumor RNA sequencing were performed to identify molecular targets for potential matched therapy. A multidisciplinary molecular tumor board issued treatment recommendations based on the genomic results, blood–brain barrier penetration of the indicated therapies, drug–drug interactions, and drug safety profiles. Feasibility of generating genomics-informed treatment recommendations within 35 days of surgery was assessed. Results: Of the 20 patients enrolled in the study, 16 patients had sufficient tumor tissue for analysis. Exome sequencing was completed for all patients, and RNA sequencing was completed for 14 patients. Treatment recommendations were provided within the study's feasibility time frame for 15 of 16 (94%) patients. Seven patients received treatment based on the tumor board recommendations. Two patients reached 12-month progression-free survival, both adhering to treatments based on the molecular profiling results. One patient remained on treatment and progression free 21 months after surgery, 3 times longer than the patient's previous time to progression. Analysis of matched nonenhancing tissue from 12 patients revealed overlapping as well as novel putatively actionable genomic alterations. Conclusions: Use of genome-wide molecular profiling is feasible and can be informative for guiding real-time, central nervous system–penetrant, genomics-informed treatment recommendations for patients with recurrent glioblastoma. Clin Cancer Res; 24(2); 295–305. ©2017 AACR. See related commentary by Wick and Kessler, p. 256
The Nine-Step Minnesota Grading System for Eyebank Eyes With Age Related Macular Degeneration: A Systematic Approach to Study Disease Stages
Olsen, Timothy W. , Liao, Albert , Robinson, Hershonna S., Palejwala, Neal, Sprehe, Nicholas

Mayo Clinic

Investigative Opthalmology & Visual Science | October 26, 2017 | Volume: 58 | Issue: 12 | Pages: 5497

10.1167/iovs.17-22161 | PMID 29075760 Get It

Faculty Opinions recommendation of Fatigability, exercise intolerance, and abnormal skeletal muscle energetics in heart failure.
Borlaug, Barry A.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | October 26, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.727807886.793538097 Get It

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial
Bartlett, Nancy L. , Costello, Brian A. , LaPlant, Betsy, Ansell, Stephen M. , Reeder, Craig B. , Thye, Lim Soon, Anderson, Daniel M. , Krysiak, Kilannin , Ramirez, Cody A. , Qi, Jing , Siegel, Barry A. , Griffith, Malachi , Griffith, Obi L. , Gomez, Felicia , Fehniger, Todd A. , LaPlant, Betsy R, Krysiak, Kilannin , Griffith, Malachi , Griffith, Obi L , Gomez, Felicia , Fehniger, Todd A , Bartlett, Nancy L , Kuruvilla, John , Ramirez, Cody

Mayo Clinic

Blood | October 26, 2017 | Volume: 131 | Issue: 2 | Pages: 182-190

10.1182/blood-2017-09-804641 | PMID 29074501 Get It

Key Points Ibrutinib has modest activity in FL with low response rates in rituximab-refractory patients. CARD11 mutations predict for lack of response to ibrutinib.
The management of anticoagulation in patients undergoing therapeutic plasma exchange: A concise review
Shunkwiler, Sara M., Wool, Geoffrey D. , Ipe, Tina S. , Fang, Deanna C., Biller, Elizabeth, Treml, Angela , Weiss, John, Baron, Beverly W. , Berg, Mary, AABB, On behalf of the Therapeutic Apheresis Subsection of the, Wool, Geoffrey , Ipe, Tina S , Baron, Beverly W , Pham, Huy P. , AABB, On behalf of the Therapeutic Apheresis Subsection of the

Mayo Clinic

Journal of Clinical Apheresis | October 26, 2017 | Volume: 33 | Issue: 3 | Pages: 371-379

10.1002/jca.21592 | PMID 29071747 Get It

We surveyed multiple apheresis centers represented by the authors for their clinical approach to the management of anticoagulation issues during therapeutic plasma exchange (TPE). We present the results of their practices and a review of the pertinent literature. As plasma is removed during TPE, replacement with all or partial non‐plasma‐containing fluids (eg, 5% albumin) may lead to significant changes in hemostasis. These changes are amplified in patients who are receiving anticoagulation. We discuss various anticoagulants as well as the monitoring and adjustment of anticoagulation before, during, and after TPE. No single guideline can be applied, but rather, patients must be monitored individually, taking into account their often complex clinical conditions and medication profiles.